These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19539362)

  • 1. Rivaroxaban in acute coronary syndromes: too soon to know?
    Gurm HS; Eagle K
    Lancet; 2009 Jul; 374(9683):3-4. PubMed ID: 19539362
    [No Abstract]   [Full Text] [Related]  

  • 2. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
    Ahrens I; Bode C
    Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban (Xarelto) for acute coronary syndrome.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):97. PubMed ID: 22173426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
    Aalbers J
    Cardiovasc J Afr; 2012 Oct; 23(9):525-6. PubMed ID: 23108522
    [No Abstract]   [Full Text] [Related]  

  • 7. [Secondary prevention of myocardial infarct. A new anticoagulant improves survival prospects].
    Einecke D
    MMW Fortschr Med; 2011 Dec; 153(48):14-5. PubMed ID: 22299243
    [No Abstract]   [Full Text] [Related]  

  • 8. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underestimation of the effect of bleeding in clinical trials.
    Stewart RA
    Lancet; 2009 Oct; 374(9696):1145; author reply 1145-6. PubMed ID: 19801091
    [No Abstract]   [Full Text] [Related]  

  • 10. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban for the treatment of acute coronary syndromes.
    Wong CK; White HD
    Expert Opin Pharmacother; 2013 May; 14(7):917-27. PubMed ID: 23544968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rivaroxaban at least as effective as marcumar in stroke prevention].
    Aumiller J
    MMW Fortschr Med; 2010 Dec; 152(48):14. PubMed ID: 21222327
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivaroxaban in the contemporary treatment of acute coronary syndromes.
    Alexander D; Jeremias A
    Expert Opin Investig Drugs; 2011 Jun; 20(6):849-57. PubMed ID: 21554163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy].
    Einecke D
    MMW Fortschr Med; 2012 Apr; 154(7):24. PubMed ID: 22558862
    [No Abstract]   [Full Text] [Related]  

  • 15. Rivaroxaban (Xarelto)--a new oral anticoagulant.
    Med Lett Drugs Ther; 2011 Aug; 53(1371):65-7. PubMed ID: 21860366
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rivaroxaban versus warfarin: results of the ROCKET study].
    Lipták J
    Ideggyogy Sz; 2012 Sep; 65(9-10):349-51. PubMed ID: 23126221
    [No Abstract]   [Full Text] [Related]  

  • 17. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials.
    Chatterjee S; Sharma A; Uchino K; Biondi-Zoccai G; Lichstein E; Mukherjee D
    Coron Artery Dis; 2013 Dec; 24(8):628-35. PubMed ID: 24145765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban, the first oral, direct factor Xa inhibitor.
    Fassiadis N
    Expert Opin Pharmacother; 2009 Dec; 10(18):2945-6. PubMed ID: 19925048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
    Kakar P; Watson T; Lip GY
    Curr Opin Investig Drugs; 2007 Mar; 8(3):256-65. PubMed ID: 17408122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The ATLAS ACS 2-TIMI 51 study].
    Casella G; Pavesi PC; Magnani G; Ardissino D
    G Ital Cardiol (Rome); 2012 Oct; 13(10):625-30. PubMed ID: 23022965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.